Clinical trials: Immune Responses
Celiac Disease
Immune Response in Celiac Disease on In-vitro Gluten Challenge
The main purpose of this study is to see how cells taken from the lining of the intestine behave in the laboratory with exposure to gluten and other substances that act on the immune system.
- Trial name
- NCT01909050
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Beth Israel Deaconess Medical Center
Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum
Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)
This Phase 2 study tests whether adding two immune therapies - nogapendekin alfa-inbakicept (NAI) and off-the-shelf iNKT cell infusions - to standard care can safely help critically ill adults with severe community-acquired…
- Conditions
- Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in Critically Ill Adults
- Trial name
- NCT07492888
- Testing
- Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)
- Sponsor
- ImmunityBio, Inc.
Influenza, Human
A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age
This clinical trial will study an investigational seasonal influenza vaccine in adults 18 to 64 years of age. The vaccine is based on messenger ribonucleic acid, also called mRNA.
- Trial name
- NCT07851246
- Testing
- mRNA Seasonal Flu vaccine, Comparator 1, Comparator 2
- Where
- 12 sites in United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
CIDP
Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
This study aims analyze the transcriptome to identify predictive biomarkers of IVIG in CIDP patients. 25 patients with a diagnosis of CIDP according to European criteria, naïve of treatment, will be included and followed for 1…
- Trial name
- BIOMARK (NCT02629796)
- Testing
- CIDP treated (IVIG)
- Where
- 18 sites in France
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Covid19, Cancer
A Study on the Immune-response to COVID-19 Vaccination in Cancer Patients - the IOSI-COVID-19-001 Study
This is a single centre prospective observational study to assess the immune response to SARS-CoV-2 vaccines in cancer patients receiving active treatment or in follow-up at the IOSI and in non-cancer patients (age and gender…
- Trial name
- NCT04800146
- Testing
- Blood sample
- Where
- Switzerland
- Volunteers
- 177 people, healthy volunteers welcome
- Sponsor
- Ilaria Colombo
Healthy Volunteers
Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
The purpose of this study is to assess the cellular immune responses following 2 doses given 3 months apart of tetravalent dengue vaccine candidate (TDV) in 4 to 16 years' healthy participants.
- Trial name
- NCT02948829
- Testing
- TDV
- Where
- 2 sites in Panama, Philippines
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Takeda
Hepatitis B
Compare the Immune Response & Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine vs Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis & Dialysis Patients Who Did Not Respond to Previous Hepatitis B Vaccination
Hepatitis B prevention in non-responders uraemic patients is currently based on both HBsAg surveillance and the isolation from HBsAg carriers. A more immunogenic vaccine would be a benefit for this population.
- Trial name
- NCT00291954
- Testing
- HB-AS02V, HBVAXPRO vaccine
- Where
- 25 sites in Belgium, Czechia and 1 more
- Volunteers
- 257 people
- Sponsor
- Henogen
Intra Abdominal Infections
Soluble Immune Checkpoints in Intra-Abdominal Infections
Intraabdominal infections is a life-threatening syndrome with a high incidence and a significant economic burden. The early-stage cytokine storm and the late-stage immunosuppression contribute to the mortality of sepsis.
- Trial name
- NCT07689266
- Testing
- Soluble Immune checkpoint levels
- Where
- Turkey (Türkiye)
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Istanbul Training and Research Hospital
Primary Immune Thrombocytopenia (ITP)
A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.
The purpose of this study is to assess the efficacy, safety and pharmacokinetics (PK) of ianalumab (VAY736) in addition to eltrombopag treatment; and to inform the dose of ianalumab in pediatric patients (5 to <18 years of age)…
- Trial name
- VAYHIT-P (NCT07660172)
- Testing
- Ianalumab, Eltrombopag
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Influenza Viral Infections
Single Dose Texas 2017 (H3N2) Challenge Study
The overall objective of the present study is to utilize the recombinant H3N2 (A/Texas/71/2017 (H3N2, clade 3C3a)) influenza virus for a controlled human infection model to study host responses to influenza virus with the aim of…
- Trial name
- NCT06476275
- Testing
- Influenza A/Texas/71/2017 (H3N2)
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Duke University
Fever, Respiratory Tract Infections
Diagnostic Accuracy of a Host-response Based Diagnostic Tool for Distinguishing Between Bacterial and Viral Etiologies in Pediatric Patients
This is a prospective clinical validation study of a novel regulatory approved (CE-IVD) diagnostic assay called ImmunoXpert™ that will enroll 1222 pediatric patients.
- Trial name
- AutoPilot (NCT03052088)
- Where
- 2 sites in Germany, Italy
- Volunteers
- 1,140 people
- Sponsor
- MeMed Diagnostics Ltd.
HIV Infections
Observational Study on Predictors of Response to Invirase (Saquinavir) Treatment in Treatment-naïve Patients With HIV Infection
This prospective observational study will evaluate predictors of response to Invirase (saquinavir) treatment in treatment-naïve patients with HIV infection. Data will be collected during 48 weeks of treatment.
- Trial name
- NCT01297127
- Where
- 8 sites in Poland
- Volunteers
- 151 people
- Sponsor
- Hoffmann-La Roche
Hodgkin Disease
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with…
- Trial name
- CheckMate 744 (NCT02927769)
- Testing
- Nivolumab, brentuximab vedotin, bendamustine
- Where
- 79 sites in United States, Canada and 9 more
- Volunteers
- 72 people
- Sponsor
- Bristol-Myers Squibb
Allergy and Immunology, Infection Viral
Evaluation of Immune Response in COVID-19 Patients
The aim of the project is to evaluate the immunological features of COVID-19 patients. Patients are recruited without any pharmacological treatments restriction.
- Trial name
- IMMUNOVID (NCT04438629)
- Testing
- COVID-19 treatment
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Haemophilus Influenzae Type b, Neisseria Meningitidis
Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine
The purpose of this study is to demonstrate the non-inferiority of the candidate Hib-MenC conjugate vaccine co-administered with Infanrix™-IPV versus a licensed meningococcal serogroup C vaccine co-administered with Pediacel™…
- Trial name
- NCT00258700
- Testing
- Haemophilus influenzae type b- and meningococcal (vaccine)
- Where
- 10 sites in Poland, United Kingdom
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Allergy Drug, Allergic Reaction
Preoperative Survey to Evaluate Patient Allergy
The study will only involve identification of the listed allergies from the electronic medical record and investigation into the symptoms that prompted this allergy listing.
- Conditions
- Allergy Drug, Allergic Reaction, Pediatric, Surgery
- Trial name
- NCT05670756
- Testing
- Survey
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Nationwide Children's Hospital
SARS-CoV-2, COVID-19
Vienna Versus SARS-CoV-2 Virus Study
This study examines the seroprevalence against SARS-CoV-2 in health care workers and patients at the Vienna General Hospital.
- Trial name
- VIVI (NCT04407429)
- Testing
- Laboratory Analyses
- Where
- Austria
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Influenza, Human
Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures
The aims of this vaccine trial are: (1) to measure humoral and selected cellular immune responses to repeated influenza vaccination with Flublok, including these responses' associations with age, birth year, and prior vaccination…
- Trial name
- DRIVE (NCT04576377)
- Testing
- FluBlok
- Where
- Hong Kong
- Volunteers
- 977 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Breast Cancer Stage II, Breast Cancer Stage III
Stress and Immunity Breast Cancer Project
An investigative study of the effectiveness of the BioBehavioral Intervention on Stage II/III breast cancer patients. A total of 231 patients were split between an assessment-only control group and an experimental group receiving…
- Trial name
- NCT03578627
- Testing
- BioBehavioral Intervention
- Where
- United States
- Volunteers
- 231 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Refractory Solid Tumors, Lymphoma
A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors
This is a Phase I continuous infusion study designed to explore if constant concentration over time adds to the effectiveness of terameprocol without increasing toxicity. It will also explore weekly dosing as an option.
- Trial name
- NCT00664586
- Testing
- Terameprocol (EM-1421)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Erimos Pharmaceuticals